RE:RE:RE:Q2/24 CommentsArgentina: It would certainly be a welcome change. There are promising signals but I'd say there's a lot to be done. Hopefully it works out well!
EBITDA: Agreed. I doubt that GUD, specifically, is trying to deceive us. But it would be silly to look at this number alone.
Growth: A big question is will the MOH contracts continue? Outside of that, there's a lot of potential for growth, with many of the existing products still growing, Imvexxy and Minjuvi entering their second year next year, and a much busier schedule of launches than we've ever had. The first of year of a launch will have a relatively small impact but with all of this combined, we should be looking at meaningful growth. If the MOH contracts come to a dead-end, that would obviously be an offsetting factor.
Exelon: They said from the beginning their expectation for Exelon was to maintain market share. To my understanding, this acquisition was done on decent direct financial terms, but also importantly, to provide a base for the CNS category. We now have several products in the pipeline that will benefit from Exelon's base once launched. If I had to guess, I'd say Exelon is performing according to expectations. It's just that it has taken time to bring meaningful CNS products to the play, and they never expected it to deliver incredible returns on its own.